Table 1 Characteristics of the reports of patients with Raynaud’s phenomenon involving a CGRP-targeting drug
Characteristics | Number of reports (%) |
|---|---|
Age | |
18–44 years | 29 (50.0) |
45–64 years | 27 (46.6) |
65–74 years | 2 (3.4) |
Country | |
United States of America | 62 (62.6) |
Italy | 10 (10.1) |
Germany | 5 (5.1) |
Spain | 4 (4.0) |
Ireland | 4 (4.0) |
Netherlands | 4 (4.0) |
Belgium | 2 (2.0) |
Switzerland | 2 (2.0) |
Norway | 2 (2.0) |
Austria | 1 (1.0) |
United Kingdom | 1 (1.0) |
Iceland | 1 (1.0) |
Sweden | 1 (1.0) |
Reporter qualification | |
Physician | 51 (51.5) |
Pharmacist | 3 (3.0) |
Other Health Professional | 16 (16.2) |
Consumer | 39 (39.4) |